TScan Therapeutics, Inc. TCRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -65.83% | -54.77% | 286.02% | 139.37% | 473.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -65.83% | -54.77% | 286.02% | 139.37% | 473.88% |
| Cost of Revenue | -28.29% | -26.47% | -37.18% | 20.66% | 21.42% |
| Gross Profit | 24.38% | 24.24% | 44.68% | -15.73% | -12.21% |
| SG&A Expenses | -10.48% | -4.82% | -25.39% | 6.28% | 17.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.41% | -21.60% | -34.65% | 17.50% | 20.43% |
| Operating Income | 21.11% | 19.62% | 40.46% | -13.58% | -13.31% |
| Income Before Tax | 17.84% | 16.00% | 35.83% | -19.48% | -16.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.84% | 16.00% | 35.83% | -19.48% | -16.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.84% | 16.00% | 35.83% | -19.48% | -16.71% |
| EBIT | 21.11% | 19.62% | 40.46% | -13.58% | -13.31% |
| EBITDA | 21.50% | 20.03% | 41.29% | -14.84% | -15.02% |
| EPS Basic | 31.22% | 20.91% | 36.19% | -12.33% | -8.88% |
| Normalized Basic EPS | 31.23% | 20.91% | 39.91% | -12.34% | -8.88% |
| EPS Diluted | 31.22% | 20.91% | 36.19% | -12.33% | -8.88% |
| Normalized Diluted EPS | 31.23% | 20.91% | 39.91% | -12.34% | -8.88% |
| Average Basic Shares Outstanding | 19.44% | 6.20% | 0.55% | 6.36% | 7.21% |
| Average Diluted Shares Outstanding | 19.44% | 6.20% | 0.55% | 6.36% | 7.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |